Therefore, siRNAs for cyclin B may be an effective treatment against cancers where p53 function is inhibited but the gene has not been deleted.
In this context, siRNAs targeting cyclin B could represent a promising therapeutic strategy for cancers that have impaired p53 function but still possess their corresponding gene.